This study provides a biomarker-driven combination therapy strategy for patients with CLDN18.2-positive gastric cancer, suggesting that integrating dual biomarker selection of CLDN18.2 and PD-L1 in first-line treatment could significantly improve therapeutic outcomes, offering direct guidance for the design of personalized therapies in gastric cancer.
Literature Overview
The article titled “First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial,” published in the journal Nature Medicine, systematically investigates the safety and efficacy of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma. Using a prospective cohort design, the study evaluates progression-free survival (PFS) and objective response rate (ORR) of this triplet regimen, and deeply analyzes the impact of CLDN18.2 expression levels and PD-L1 status on treatment efficacy, providing critical evidence for subsequent phase 3 validation trials.Background Knowledge
Gastric cancer (G/GEJ adenocarcinoma) is one of the leading causes of cancer-related deaths worldwide, with a poor prognosis in advanced stages, where median overall survival is typically less than 14 months. Although first-line chemotherapy combined with PD-1 inhibitors has shown survival benefits in some patients, the lack of effective biomarkers to guide treatment continues to limit the development of precision therapies. CLDN18.2, a tight junction protein specifically expressed in gastric epithelial cells, becomes exposed on the cell surface after malignant transformation, making it a highly promising therapeutic target. A phase 3 trial has already confirmed that the CLDN18.2-targeted antibody zolbetuximab, when combined with chemotherapy, significantly improves PFS and OS in CLDN18.2-positive patients. However, responses to single-agent targeted or immunotherapies remain limited, and enhancing antitumor immune responses through combination strategies has become a major research challenge. This study focuses on the biological rationale for synergy between CLDN18.2 targeting and PD-1 inhibition, proposing that zolbetuximab may enhance the antitumor effects of PD-1 blockade by inducing immunogenic cell death and increasing T-cell infiltration, thus providing a theoretical foundation for developing more effective first-line combination regimens.
Research Methods and Experiments
The study is based on the global, multicenter, open-label phase 2 ILUSTRO trial, which enrolled 77 patients with HER2-negative, unresectable or metastatic CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma, divided into safety lead-in (Cohort 4A) and expansion phases (Cohort 4B). All patients received zolbetuximab (800 mg/m² loading dose) in combination with mFOLFOX6 and nivolumab. The primary efficacy endpoint was investigator-assessed PFS, with secondary endpoints including ORR, DOR, OS, and safety. Efficacy was analyzed stratified by CLDN18.2 expression level—high (≥75% of tumor cells with strong membrane staining) versus moderate (50–75%)—and exploratory analyses incorporated PD-L1 CPS status. Tumor assessments followed RECIST v1.1 criteria, conducted every 8 weeks until disease progression. Central IHC testing was used for CLDN18.2 and PD-L1 expression to ensure consistency.Key Conclusions and Perspectives
Research Significance and Prospects
This study marks a new stage in CLDN18.2-targeted therapy, transitioning from single-pathway inhibition to multi-mechanistic synergy. Its success positions CLDN18.2 at the core of precision therapy for gastric cancer and has catalyzed the phase 3 LUCERNA trial, which uses dual expression of CLDN18.2 and PD-L1 as enrollment criteria, potentially establishing a new standard of care. For drug development, it demonstrates that targeting tight junction proteins can effectively activate antitumor immunity, providing a template for similar strategies in other solid tumors. From a clinical monitoring perspective, the study underscores the need to standardize CLDN18.2 IHC testing procedures to ensure consistent results. Additionally, it provides clear efficacy endpoints and biomarker combinations for building more clinically relevant disease models (e.g., humanized mouse models), facilitating drug screening and mechanistic validation.
Conclusion
This study establishes zolbetuximab in combination with mFOLFOX6 and nivolumab as a highly effective and tolerable first-line regimen for CLDN18.2-positive gastric cancer, achieving a median PFS of 14.8–18.0 months, substantially surpassing current standard therapies. Its core value lies in validating the clinical utility of CLDN18.2 as a functional biomarker and revealing its synergistic predictive power with PD-L1 status, providing robust evidence for precision-based stratified treatment. From bench to bedside, this work not only advances targeted-immunotherapy combination strategies but also sets a new benchmark for personalized treatment pathways in gastric cancer. In the future, CLDN18.2-based combination therapies are poised to become standard options for specific patient populations, supported by corresponding diagnostic systems and animal models, ultimately improving patient survival and quality of life.
